If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Renal Cell Carcinoma Clinical Trials

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (FLIPPER)

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (MACS1760)

An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

AMG 172 First in Human Study in Patients With Kidney Cancer

Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD 4)

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (CROSS-J-RCC)

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma (5-AZ)

A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma (AGuo)

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Interleukin 2, Aldesleukin and Entinostat for Kidney Cancer

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma (EVERMORE)

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma

Tumor Registry of Advanced Renal Cell Carcinoma (RCC-Registry)

VEGF Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma (Everolimage)

Association Between Hepatitis C Infection and Renal Cell Carcinoma

Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer

Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Renal Nutrition Update


Renal Nutrition Update

Advanced glycation end products (AGEs) are byproducts of non-enzymatic chemical reactions between sugars and amino acids, lipids, or DNA. A wide range of molecules fall into this category.

Newsletters

Sign up to start receiving free e-newsletters from Renal & Urology News, including:

  • Latest News
  • Latest CME
  • Ongoing Clinical Trials
  • Conference Highlights
  • Expert Q&A

Current Poll


Has a radiologist ever challenged one of your orders for an imaging procedure?

Click here to take the poll

Cartoons

On The Forefront


On The Forefront

A 55-year-old Caucasian woman initially presented to one of Cleveland Clinic's regional outpatient urology clinics with gross hematuria and an obstructing right ureteral stone.

Clinical Quiz


Small Renal Masses and Drug-Eluting Stents — How to Best Balance the Risks?



A 55-year-old male with significant history of coronary artery disease is found to have an intraparenchymal 2 cm left-enhancing small renal mass. Answer the quiz correctly and you'll have a chance to win an American Express gift card.

 Subscribe to the RSS for this page  [view all our RSS feeds here]
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Kidney Cancer Overactive Bladder Prostate Cancer PSA Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions